Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1;12(1):e2020045.
doi: 10.4084/MJHID.2020.045. eCollection 2020.

Acquired Haemophilia A: An Intriguing Disease

Affiliations
Review

Acquired Haemophilia A: An Intriguing Disease

Maria Gabriella Mazzucconi et al. Mediterr J Hematol Infect Dis. .

Abstract

. Acquired Haemophilia A is a rare acquired bleeding disorder caused by Factor VIII autoantibodies, which neutralise FVIII activity. These inhibitors differ from alloantibodies against FVIII, which can occur in congenital Haemophilia A after repeated exposures to plasma-derived or recombinant FVIII products. In most cases, the disease occurs suddenly in subjects without a personal or familiar history of bleedings, with symptoms that may be mild, moderate, or severe. However, only laboratory alterations are present in ~ 30% of patients. The incidence varies from 1 to 4 cases per million/year; more than 80% of patients are elderly, males and females are similarly affected. There is a small peak of incidence related to pregnancy in young women aged 20-40 years. The disease may be underdiagnosed in the elderly. The diagnostic algorithm is based on an isolated prolonged activated partial thromboplastin time, normal thrombin time, absence of Lupus Anticoagulant, and a mixing test that reveals the presence of an inhibitor: the finding of reduced FVIII activity and the detection of neutralising autoantibodies against FVIII lead to the diagnosis. The disease is idiopathic in 44%-63% of cases, while in the others etiological factors are present. Bleeding prevention and treatment are based on therapeutic tools as by-passing agents, recombinant porcine FVIII concentrate or, in a limited number of cases, FVIII concentrates and desmopressin. As soon as the diagnosis has been made, immunosuppressive therapy must be started to eradicate the inhibitor. Better knowledge of the disease, optimal management of bleeding and eradication of the inhibitor have significantly reduced morbidity and mortality in most patients.

Keywords: autoantibodies against FVIII; bleeding symptoms; bleeding treatment; eradication therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
Legend. aPTT = activated partial thromboplastin time; DIC = disseminated intravascular coagulation; DTI = direct thrombin inhibitor; FVIII = factor VIII; FIX = factor IX; FXI = factor XI; FXII = factor XII; PT = prothrombin time; ratio = test plasma time/normal reference plasma time; TCT=thrombin clotting time.

References

    1. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21–35. doi: 10.1046/j.1365-2141.2003.04162.x. - DOI - PubMed
    1. Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired haemophilia. Haemophilia. 2010;16(Suppl 3):41–45. doi: 10.1111/j.1365-2516.2010.02259.x. - DOI - PubMed
    1. Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010;89:607–612. doi: 10.1007/s00277-009-0887-3. - DOI - PubMed
    1. Pavlova A, Zeitler H, Scharrer I, Brackmann HH, Oldenburg J. HLA genotype in patients with acquired haemophilia A. Haemophilia. 2010;16:107–112. doi: 10.1111/j.1365-2516.2008.01976.x. - DOI - PubMed
    1. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost. 2007;5(5):893–900. doi: 10.1111/j.1538-7836.2007.02433.x. - DOI - PubMed